Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Colorcon
Fish and Richardson
Moodys
Fuji
QuintilesIMS
Citi
UBS
Merck

Generated: November 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207223

« Back to Dashboard

NDA 207223 describes DIACOMIT, which is a drug marketed by Biocodex Sa and is included in two NDAs. It is available from one supplier. Additional details are available on the DIACOMIT profile page.

The generic ingredient in DIACOMIT is stiripentol. One supplier is listed for this compound. Additional details are available on the stiripentol profile page.
Summary for 207223
Tradename:DIACOMIT
Applicant:Biocodex Sa
Ingredient:stiripentol
Patents:0
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 207223
Generic Entry Date for 207223*:
Constraining patent/regulatory exclusivity:
INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
Dosage:
FOR SUSPENSION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 207223
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DIACOMIT stiripentol FOR SUSPENSION;ORAL 207223 NDA BIOCODEX INC. 68418-7941 68418-7941-6 60 PACKET in 1 CARTON (68418-7941-6) > 250 mg in 1 PACKET (68418-7941-1)
DIACOMIT stiripentol FOR SUSPENSION;ORAL 207223 NDA BIOCODEX INC. 68418-7942 68418-7942-6 60 PACKET in 1 CARTON (68418-7942-6) > 500 mg in 1 PACKET (68418-7942-1)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrength250MG/PACKET
Approval Date:Aug 20, 2018TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 20, 2025
Regulatory Exclusivity Use:INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
Regulatory Exclusivity Expiration:Aug 20, 2023
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrength500MG/PACKET
Approval Date:Aug 20, 2018TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 20, 2025
Regulatory Exclusivity Use:INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
McKesson
Fish and Richardson
Covington
Boehringer Ingelheim
Farmers Insurance
Healthtrust
Argus Health
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.